Literature DB >> 21671175

Role of RANTES and its receptor in gastric cancer metastasis.

Zhixin Cao1, Xiangshang Xu1, Xuelai Luo1, Li Li2, Bin Huang3, Xiaolan Li1, Deding Tao1, Junbo Hu1, Jianping Gong4.   

Abstract

This study examined the role of regulated upon activation normal T cell expressed and secreted (RANTES) and its receptor C-C chemokine receptor type 5 (CCR5) in gastric cancer metastasis and the associated mechanism. The expression of RANTES and CCR5 was detected by using immunohistochemical staining and Western blotting in the gastric cancer tissues obtained from 60 gastric cancer patients with or without lymph node metastasis (n=30 in each). The results showed that the expression levels of RANTES and CCR5 were higher in gastric cancer with lymph node metastasis than in that without metastasis (P<0.05). The expression levels of RANTES in 30 lymph nodes with cancerous invasion were higher than in 30 normal lymph nodes (P<0.05). Chemotactic test revealed that the number of migrating gastric cancer cells (n=295.0 ± 54.6) induced by the protein of cancer-invading lymph nodes was greater than that by the protein mixture from cancer-invading lymph nodes and RANTES antibody (n=42.5 ± 11.6) (P<0.05). RT-PCR showed that the expression levels of the main Th1 cytokines (IL-2, Γ-IFN) were lower in gastric cancer with lymph node metastasis (2.22 ± 0.90, 3.26 ± 1.15 respectively) than in that without metastasis (3.07 ± 1.67, 4.77 ± 1.52 respectively) (P<0.05), but the expression level of the main Th 2 cytokine (IL-10) was higher in gastric cancer with lymph nodes metastasis (6.06 ± 2.04) than in that without metastasis (4.88 ± 1.87) (P<0.05). It was concluded that RANTES and its receptor CCR5 may contribute to gastric cancer metastasis through influencing the balance of Th1/Th2. RANTES and CCR5 may become a marker of gastric cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671175     DOI: 10.1007/s11596-011-0378-3

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  28 in total

Review 1.  Chemokines and disease.

Authors:  C Gerard; B J Rollins
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

Review 2.  The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.

Authors:  Neora Yaal-Hahoshen; Sima Shina; Leonor Leider-Trejo; Itay Barnea; Esther L Shabtai; Elina Azenshtein; Iulia Greenberg; Iafa Keydar; Adit Ben-Baruch
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

3.  Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma.

Authors:  G Luboshits; S Shina; O Kaplan; S Engelberg; D Nass; B Lifshitz-Mercer; S Chaitchik; I Keydar; A Ben-Baruch
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

4.  A dual role for tumor-derived chemokine RANTES (CCL5).

Authors:  Evan P Adler; Charles A Lemken; Nicholas S Katchen; Robert A Kurt
Journal:  Immunol Lett       Date:  2003-12-15       Impact factor: 3.685

5.  A chemokine receptor antagonist inhibits experimental breast tumor growth.

Authors:  Stephen C Robinson; Kate A Scott; Julia L Wilson; Richard G Thompson; Amanda E I Proudfoot; Frances R Balkwill
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

6.  Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions.

Authors:  Gali Soria; Neora Yaal-Hahoshen; Elina Azenshtein; Sima Shina; Leonor Leider-Trejo; Larisa Ryvo; Efrat Cohen-Hillel; Alex Shtabsky; Marcelo Ehrlich; Tsipi Meshel; Iafa Keydar; Adit Ben-Baruch
Journal:  Cytokine       Date:  2008-09-13       Impact factor: 3.861

Review 7.  Cancer CXC chemokine networks and tumour angiogenesis.

Authors:  Robert M Strieter; Marie D Burdick; Javier Mestas; Brigitte Gomperts; Michael P Keane; John A Belperio
Journal:  Eur J Cancer       Date:  2006-02-28       Impact factor: 9.162

Review 8.  The inflammatory chemokines CCL2 and CCL5 in breast cancer.

Authors:  Gali Soria; Adit Ben-Baruch
Journal:  Cancer Lett       Date:  2008-04-24       Impact factor: 8.679

9.  Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type.

Authors:  Donald Earl Henson; Christopher Dittus; Mamoun Younes; Hong Nguyen; Jorge Albores-Saavedra
Journal:  Arch Pathol Lab Med       Date:  2004-07       Impact factor: 5.534

10.  Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.

Authors:  Donatella Aldinucci; Debora Lorenzon; Lara Cattaruzza; Antonio Pinto; Annunziata Gloghini; Antonino Carbone; Alfonso Colombatti
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

View more
  10 in total

1.  C-C motif chemokine receptors in gastric cancer.

Authors:  Hyewon Ryu; Seung Woo Baek; Ji Young Moon; In-Sook Jo; Nayoung Kim; Hyo Jin Lee
Journal:  Mol Clin Oncol       Date:  2017-10-27

2.  Chemokine Ligand 5 to Predict Optimal Cytoreduction in Ovarian Cancer.

Authors:  Yudi Mulyana Hidayat; Ali Budi Harsono; Gatot Nyarumenteng Adhipurnawan Winarno; Siti Salima
Journal:  Int J Gen Med       Date:  2020-11-20

3.  CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination.

Authors:  Andrea Mencarelli; Luigina Graziosi; Barbara Renga; Sabrina Cipriani; Claudio D'Amore; Daniela Francisci; Angela Bruno; Franco Baldelli; Annibale Donini; Stefano Fiorucci
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

4.  Characterization and Clinical Implication of Th1/Th2/Th17 Cytokines Produced from Three-Dimensionally Cultured Tumor Tissues Resected from Breast Cancer Patients.

Authors:  Anna Kiyomi; Masujiro Makita; Tomoko Ozeki; Na Li; Aiko Satomura; Sachiko Tanaka; Kenji Onda; Kentaro Sugiyama; Takuji Iwase; Toshihiko Hirano
Journal:  Transl Oncol       Date:  2015-08       Impact factor: 4.243

Review 5.  The role of chemoattractant receptors in shaping the tumor microenvironment.

Authors:  Jiamin Zhou; Yi Xiang; Teizo Yoshimura; Keqiang Chen; Wanghua Gong; Jian Huang; Ye Zhou; Xiaohong Yao; Xiuwu Bian; Ji Ming Wang
Journal:  Biomed Res Int       Date:  2014-07-10       Impact factor: 3.411

6.  rs12416605:C>T in MIR938 associates with gastric cancer through affecting the regulation of the CXCL12 chemokine gene.

Authors:  Ignasi Torruella-Loran; María Karla Ramirez Viña; Daniela Zapata-Contreras; Xavier Muñoz; Eva Garcia-Ramallo; Catalina Bonet; Carlos A Gonzalez; Núria Sala; Yolanda Espinosa-Parrilla
Journal:  Mol Genet Genomic Med       Date:  2019-07-04       Impact factor: 2.183

Review 7.  The inflammatory chemokine CCL5 and cancer progression.

Authors:  Donatella Aldinucci; Alfonso Colombatti
Journal:  Mediators Inflamm       Date:  2014-01-02       Impact factor: 4.711

Review 8.  Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.

Authors:  Donatella Aldinucci; Naike Casagrande
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

Review 9.  Metabolomics as an Approach to Characterise the Contrasting Roles of CCR5 in the Presence and Absence of Disease.

Authors:  Anandi Rautenbach; Aurelia A Williams
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923

Review 10.  Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease.

Authors:  Joseph Pierre Aboumsallem; Javid Moslehi; Rudolf A de Boer
Journal:  J Am Heart Assoc       Date:  2020-01-21       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.